National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

posaconazole
A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Noxafil
Code name:SCH 56592



Previous:pomegranate liquid extract, pomegranate-extract pill, POMx, porfimer sodium, porfiromycin
Next:povidone-iodine solution, PP14 derivative-treated HLA-matched donor mononuclear cell-enriched leukocytes, PPI-2458, PR-104, PR-171

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov